Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension

American Journal of Hypertension

Volumn 28, Issue 1, 2015, Pages 22-29

  Raptis, Athanasios E ^a   Markakis, Konstantinos P ^a   Mazioti, Maria C ^a   Ikonomidis, Ignantios ^a   Maratou, Eirini P ^b   Vlahakos, Dimitrios V ^a   Kotsifaki, Eleni E ^a   Voumvourakis, Asterios N ^a   Tsirogianni, Alexandra G ^c   Lambadiari, Vaia A ^a   Lekakis, John P ^a   Raptis, Sotirios A ^a,b   Dimitriadis, George D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic National Center for Research   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Aliskiren; Arterial stiffness; Blood pressure; Diabetes mellitus; Endothelial progenitor cells; Hypertension; Vascular function

Indexed keywords

ALISKIREN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; AMIDE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; FUMARIC ACID DERIVATIVE;

ADULT; AORTIC AUGMENTATION INDEX; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY FLOW MEDIATED DILATATION; BRACHIAL BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CELL CULTURE; CENTRAL AORTIC SYSTOLIC PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; ENDOTHELIAL PROGENITOR CELL; ESSENTIAL HYPERTENSION; FEMALE; GLYCEMIC CONTROL; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HUMAN; HUMAN CELL; LEFT VENTRICULAR TWISTING; LEFT VENTRICULAR UNTWISTING; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGED; ARTERIAL PRESSURE; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PILOT STUDY; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG SUBSTITUTION; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FUMARATES; HEMODYNAMICS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 84922386166     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu119     Document Type: Article

References (40)

1. Palatini P CE, Gasowski J, Gluszek J, Jankowski P, Narkiewicz K, Saladini F, Stolarz-Skrzypek K, Tikhonoff V, Van Bortel L, Wojciechowska W, Kawecka-Jaszcz K. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag 2011; 7:725-739.
2. Lekakis J AP, Balbarini A, Blann A, Boulanger C, Cockcroft J, Cosentino F, Deanfield J, Gallino A, Ikonomidis I, Kremastinos D, Landmesser U, Protogerou A, Stefanadis C, Tousoulis D, Vassalli G, Vink H, Werner N, Wilkinson I and Vlachopoulos C. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011; 18:775-789.
3. Mancia G FR, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
4. Brunner HCJ, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ; Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23: 233-246.
5. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570-2581.
6. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16:120-126.
7. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 2007; 30:1305-1313.
8. Qian C, Schoemaker RG, van Gilst WH, Roks AJ. The role of the reninangiotensin- aldosterone system in cardiovascular progenitor cell function. Clin Sci 2009; 116:301-314.
9. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89:E1-E7.
10. Chen J, Xiao X, Chen S, Zhang C, Chen J, Yi D, Shenoy V, Raizada MZ, Zhao B, Chen Y. Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy. Hypertension 2013; 61:681-689.
11. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL, Chen JW. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stressmediated mechanisms. Diabetes 2007; 56:1559-1568.
12. Hill JM, Zalos G, Halcox JP, Scenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New Engl J Med 2003; 348:593-600.
13. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, Wassmann K, Werner N, Petoumenos V, Nickenig G, Wassmann S. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 2011; 58:394-403.
14. Durik M, Seva Pessoa B, Roks AJ. The renin-angiotensin system, bone marrow and progenitor cells. Clin Sci (Lond) 2012; 123:205-223.
15. Yu Y, Fukuda N, Yao EH, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008; 21:72-77.
16. Poss J, Werner C, Lorenz D, Gensch C, Bohm M, Laufs U. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Basic Res Cardiol 2010; 105:725-735.
17. Cherney DZ, Scholey JW, Jiang S, Har R, Lai V, Sochett EB, Reich HN. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care 2012; 35:2324-2330.
18. Takeuchi M, Borden WB, Nakai H, Nishikage T, Kokumai M, Nagakura T, Otani S, Lang RM. Reduced and delayed untwisting of the left ventricle in patients with hypertension and left ventricular hypertrophy: a study using two-dimensional speckle tracking imaging. Eur Heart J 2007; 28:2756-2762.
19. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101:23F-33F.
20. Fadini GP, de Kreutzenberg S, Albiero M, Coracina A, Pagnin E, Baesso I, Cignarella A, Bolego C, Plebani M, Nardelli GB, Sartore S, Agostini C, Avogaro A. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler Thromb Vasc Biol 2008; 28:997-1004.
21. Dessapt-Baradez C, Reza M, Sivakumar G, Hernandez-Fuentes M, Markakis K, Gnudi L, Karalliede J. Circulating vascular progenitor cells and central arterial stiffness in polycystic ovary syndrome. PloS One 2011; 6:e20317.
22. Ikonomidis I, Ntai K, Kadoglou N.P, Papadakis I, Kornelakis M, Tritakis V, Varoudi M, Papadima T, Triantafyllidi H, Parissis J, Paraskevaidis I, Lekakis J. The evaluation of pulse wave velocity using Arteriograph and Complior apparatus across multiple cohorts of cardiovascular-related diseases. Int J Cardiol 2013; 168:4890-4892.
23. Karatzis EN, Ikonomidis I, Vamvakou GD, Papaioannou TG, Protogerou AD, Andreadou I, Voidonikola PT, Karatzi KN, Papamichael CM, Lekakis JP. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006; 98:1424-1428.
24. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 1989; 30:305-315.
25. Jentzsch AM, Bachmann H, Furst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free Rad Biol Med 1996; 20:251-256.
26. Loomans CJ, de Koning EF, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld A-J. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53:195-199.
27. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106:2781-2786.
28. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45:526-529.
29. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2004; 18:203-209.
30. Benndorf RA, Gehling UM, Appel D, Maas R, Schwedhelm E, Schlagner K, Silberhorn E, Hossfeld DK, Rogiers X, Boger R. Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension. Stem Cells Dev 2007; 16:329-338.
31. Flammer A.J, Gossl M, Li J, Reriani M, Shonyo S, Loeffler D, Herrmann J, Lerman LO, Lerman A. Renin inhibition with aliskiren lowers circulating endothelial progenitor cells in patients with early atherosclerosis. J Hypertens 2013; 31:632-635.
32. Bonadei I, Vizzardi E, D'Aloia A, Sciatti E, Raddino R, Metra M. Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. J Clin Hypertens 2014; 16:202-206.
33. Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, Spiering W. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013; 31:393-403.
34. Virdis A, Ghiadoni L, Qasem A.A, Lorenzini G, Duranti E, Cartoni G, Bruno RM, Bernini G, Taddei S. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33:1530-1538.
35. Umemura T, Soga J, Hidaka T, Takemoto H, Nakamura S, Jitsuiki D, Nishioka K, Goto C, Teragawa H, Yoshizumi M, Chayama K, Higashi Y. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens 2008; 21:1203-1209.
36. Kubota Y, Takahashi H, Asai K, Yasutake M, Mizuno K. The influence of a direct renin inhibitor on the central blood pressure. J Nippon Medical School 2013; 80:25-33.
37. Chou CL, Pang CY, Lee TJ, Fang TC. Direct renin inhibitor prevents and ameliorates insulin resistance, aortic endothelial dysfunction and vascular remodeling in fructose-fed hypertensive rats. Hypertens Res 2013; 36:123-128.
38. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52:563-572.
39. Zhang W, Han Y, Meng G, Bai W, Xie L, Lu H, Shao Y, Wei L, Pan S, Zhou S, Chen Q, Ferro A, Ji Y. Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats. J Am Heart Assoc 2014; 3:e000606.
40. Kumar R, Yong QC, Thomas CM, Baker KM. Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 302:R510-R517.